Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer | Zendy

Kotoe Takayoshi | Zendy; Hitoshi Kusaba | Zendy; Masato Uenomachi | Zendy; Kenji Mitsugi | Zendy; Chinatsu Makiyama | Zendy; Akitaka Makiyama | Zendy; Keita Uchino | Zendy; Tsuyoshi Shirakawa | Zendy; Yoshihiro Shibata | Zendy; Yudai Shinohara | Zendy; Kyoko Inadomi | Zendy; Kenji Tsuchihashi | Zendy; Shuji Arita | Zendy; Hiroshi Ariyama | Zendy; Taito Esaki | Zendy; Koichi Akashi | Zendy; Eishi Baba | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer

Author(s) -

Kotoe Takayoshi,

Hitoshi Kusaba,

Masato Uenomachi,

Kenji Mitsugi,

Chinatsu Makiyama,

Akitaka Makiyama,

Keita Uchino,

Tsuyoshi Shirakawa,

Yoshihiro Shibata,

Yudai Shinohara,

Kyoko Inadomi,

Kenji Tsuchihashi,

Shuji Arita,

Hiroshi Ariyama,

Taito Esaki,

Koichi Akashi,

Eishi Baba

Publication year - 2017

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-017-3371-0

Subject(s) - medicine , bevacizumab , capecitabine , oxaliplatin , irinotecan , regimen , chemotherapy , gastroenterology , chemotherapy regimen , colorectal cancer , ampulla of vater , adverse effect , surgery , cancer , carcinoma

Standard therapy for advanced small bowel adenocarcinoma (SBA) has not yet been established. The present study assessed the efficacy and safety of chemotherapy (CT) in association with molecular targeting approaches for SBA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research